Moneycontrol
HomeNewsOpinionCOVID-19 | Liquidity package will ease stress, but hangover is too intense

COVID-19 | Liquidity package will ease stress, but hangover is too intense

Given the weak backdrop and a dire future outlook, the severity of the long duration COVID-19 shock raises serious concerns about lasting damage to output and productivity

May 15, 2020 / 10:29 IST
Story continues below Advertisement

On May 13, the government eased liquidity constraints of the micro, small and medium businesses (MSMEs) and shadow banks (the non-banking financial companies or NBFCs), with an aim to help them weather the COVID-19 downturn.

For MSMEs, this is mainly an emergency credit guarantee line of Rs 3 lakh crore for an estimated 45 lakh units, which can avail of fully-guaranteed loans up to 20 percent of credit outstanding (standard assets) for four years with principal repayments of a year’s moratorium. A sum of Rs 20,000 crore of subordinate debt assistance in the form of equity support by banks (Rs 4,000 crore of government credit guarantee) will be given to another 2 lakh stressed units. A ‘Fund of Funds’ with Rs 10,000 crore corpus and 5x leverage will be formed for equity funding for viable MSMEs with growth potential.

Story continues below Advertisement

These apart, the MSME definition will be changed for scaling-up, i.e. increase in investment limits, adding turnover and removing distinction in manufacturing and services. Market protection or lesser competition was also given by excluding global tenders from public procurement up to Rs 200 crore.

The NBFCs (non-banking financial companies), which are important lending counterparts and fund-starved despite the Reserve Bank of India’s (RBI’s) special credit lines due to banks’ risk-aversion also got liquidity support: a Rs 30,000 crore Special Liquidity Scheme for investing in primary and secondary market transactions in investment grade debt with full government guarantee and Rs 45,000 crore for expanding reach of the December 2019 partial credit guarantee scheme to enable public sector banks for buying high-rated pooled assets from NBFCs with stronger balance sheets — sub-grade debt or AA, unrated papers of lower-rated NBFC borrowers — and increased first loss bearing by the government (20 percent as against 10 percent before).

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show